Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Shaw

Showing results (621-630 of 742) with videos related to

Pageof 75
Sort By:
The Journal of Infection|September 5, 2001
Antiretroviral therapy for HIV-2 infected patientsN A Smith, T Shaw, N Berry, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 1, 2019
Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK InhibitorsJessica J Lin, Adam J Schoenfeld, Viola W Zhu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 4, 2023
Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 MutationsAlessandra Bearz, Jean-François Martini, Jacek Jassem, et al.
Lung Cancer (Amsterdam, Netherlands)|December 10, 2021
Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 studyD S-W Tan, M Thomas, D-W Kim, et al.
The Journal of Physical Chemistry. B|July 10, 2019
Antioxidant Sensing by Spiropyrans: Substituent Effects and NMR Spectroscopic StudiesJoel Garcia, J Bennett Addison, Stephen Z Liu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 11, 2012
A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancerSarah B Goldberg, Jeffrey G Supko, Joel W Neal, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 25, 2010
Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancerSai-Hong Ignatius Ou, Lyudmila Bazhenova, D Ross Camidge, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 19, 2020
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX studyT Mok, D R Camidge, S M Gadgeel, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 22, 2015
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancerRebecca S Heist, Dan G Duda, Dushyant V Sahani, et al.
The Journal of Organic Chemistry|January 27, 2016
Toward Structural Correctness: Aquatolide and the Importance of 1D Proton NMR FID ArchivingGuido F Pauli, Matthias Niemitz, Jonathan Bisson, et al.
Pageof 75

Showing results (621-630 of 742) with videos related to

Sort By:
Pageof 75
The Journal of Infection|September 5, 2001
Antiretroviral therapy for HIV-2 infected patientsN A Smith, T Shaw, N Berry, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 1, 2019
Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK InhibitorsJessica J Lin, Adam J Schoenfeld, Viola W Zhu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 4, 2023
Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 MutationsAlessandra Bearz, Jean-François Martini, Jacek Jassem, et al.
Lung Cancer (Amsterdam, Netherlands)|December 10, 2021
Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 studyD S-W Tan, M Thomas, D-W Kim, et al.
The Journal of Physical Chemistry. B|July 10, 2019
Antioxidant Sensing by Spiropyrans: Substituent Effects and NMR Spectroscopic StudiesJoel Garcia, J Bennett Addison, Stephen Z Liu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 11, 2012
A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancerSarah B Goldberg, Jeffrey G Supko, Joel W Neal, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 25, 2010
Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancerSai-Hong Ignatius Ou, Lyudmila Bazhenova, D Ross Camidge, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 19, 2020
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX studyT Mok, D R Camidge, S M Gadgeel, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 22, 2015
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancerRebecca S Heist, Dan G Duda, Dushyant V Sahani, et al.
The Journal of Organic Chemistry|January 27, 2016
Toward Structural Correctness: Aquatolide and the Importance of 1D Proton NMR FID ArchivingGuido F Pauli, Matthias Niemitz, Jonathan Bisson, et al.
Pageof 75